POINT Biopharma Global (NASDAQ:PNT) is accelerating the development of precision medicines for the treatment of cancer, with a late- and early-stage pipeline of radiopharmaceuticals, a technology platform for pipeline...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Altamira’s Bentrio nasal spray approved in Malaysia
Altamira Therapeutics’ (NASDAQ:CYTO) Bentrio nasal spray has been approved by the Medical Device Authority of Malaysia for the protection against airborne allergens and viruses and is cleared for commercialization in...
Dyadic introduces novel method to produce synthetic cannabinoids
Dyadic International (NASDAQ:DYAI) has engineered its C1-cell protein production platform to demonstrate the potential of manufacturing therapeutically viable and commercially useful cannabis compounds, including...
FSD launches new corporate website to convey its emerging position in pharma
FSD Pharma (NASDAQ, CSE:HUGE; FRA:0K9A) launched a newly designed website to convey its emerging position within the biopharmaceutical industry and its ongoing commitment to bring novel treatment solutions for brain and...
IntelGenx resumes dosing in Montelukast VersaFilm Phase 2a AD trial
IntelGenx (TSX:IGX; OTCQB:IGXT) announced that patient dosing has resumed in the ongoing Phase 2a BUENA clinical trial in patients with mild-to-moderate Alzheimer’s disease (AD) under a previously amended protocol using...
BTIG cuts Acutus Medical to neutral from buy
BTIG downgraded Acutus Medical (NASDAQ:AFIB) to “neutral” from “buy” and removed its price target, citing a forecast of flat sales in 2022, among other things. The stock closed at $2.46 on Jan. 19. Acutus is a cardiac...
SVB Leerink ups Calithera to OP from MP; PT to $3 from $1
SVB Leerink upgraded Calithera Biosciences (NASDAQ:CALA) to “outperform” from “market perform” and raised its price target to $3 from $1. The stock closed at 49 cents on Jan. 19. “We conducted a deeper dive on...
Maxim starts Kiora Pharma at buy; PT $2.50
Maxim Group initiated coverage of Kiora Pharmaceuticals (NASDAQ:KPRX) with a “buy” rating and price target of $2.50. The stock closed at 80 cents on Jan. 18. Kiora is developing ophthalmic medicines including, KIO-101...
Maxim starts INVO Bioscience at buy; PT $7
Maxim Group launched coverage of INVO Biosciences (NASDAQ:INVO) with a “buy” rating and $7 price target. The stock closed at $3.69 on Jan. 18. INVO is a commercial-stage company with the world’s first and only...
University of Cambridge begins COVID-19 trial with PharmaJet needle-free system
PharmaJet’s needle-free Injection system will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University...
Maxim ups Daré Biosciences PT to $4 from $3
Maxim Group raised its price target for Daré Bioscience (NASDAQ:DARE) to $4 from $3, citing FDA approval of XACIATO vaginal gel as a treatment for bacterial vaginosis (BV) and a commercial launch in 2022. The stock...
FSD Pharma’s Dr. Eleanor Fish named to Order of Canada
Eleanor Fish, Ph.D., a member of FSD Pharma’s (NASDAQ, CSE:HUGE; FRA: 0K9A) research and clinical advisory board, was appointed to the Order of Canada for her contributions to immunology, including her ground-breaking...
Profound Medical treats first patients in Level 1 post-market study comparing TULSA procedure to radical prostatectomy
Profound Medical (NASDAQ:PROF; TSX:PRN) treated the first patients in the Level 1 CAPTAIN trial comparing the TULSA procedure (performed with its TULSA-PRO system) against radical prostatectomy (RP). The prospective...
Just a few of the companies we’ve highlighted along the way
